A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant

Renal Transplantation Clinical Trial

Official title:
A Prospective, Randomized, Open, Multicentric Study Intended to Evaluate the Efficacy and Tolerability of Sequential Treatment Based on Rabbit Anti-T-lymphocyte Serum, of Mycophenolate Mofetil and of Cyclosporin, Without Concomitant Corticosteroids, After a First Cadaveric Renal Transplant

Status Completed

Clinical Trial Summary

The trial is planned as a multicentric, randomized, prospective, open study in accordance with a 1/1 plan, on parallel groups and 2 arms of treatment. A total of 200 patients with chronic renal insufficiency, included in the French national waiting list of the Establishment Français des Greffes [French Transplants Institution] and receiving a first renal transplant will be included, after signed agreement, in this study. All the patients will receive organs taken from brain-dead subjects. The patients will be given immunosuppressant treatment based on rabbit anti-T lymphocyte serum, CellCeptÒ and NeoralÒ cyclosporin. One group of 100 randomised patients will be given standard corticosteroid therapy as well during the first six months following the transplant. This group will be compared with a second group of 100 randomised patients who will be given a single dose of corticosteroids. The main aim of this study is to evaluate the number of acute rejection episodes in patients given a first renal transplant and subjected to an immunosuppressant protocol not containing corticosteroids. The hypothesis which is proposed is that, in the absence of corticosteroids and/or calcineurin inhibitors (i.e. cyclosporin and tacrolimus), antilymphocyte serum results in a certain state of "tolerance" in respect of the allograft. The second objective concerns the beneficial effect which the absence of corticosteroids may have on short- and long-term postoperative morbidity and mortality. One may in fact assume that the absence of corticosteroids will result in an extension of the transplant patient's life expectancy as a result of the reduction in cardiovascular complications. Cardiovascular complications are the most frequent cause of death after a renal transplant.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Renal Transplantation

Clinical Trial Details

NCT number	NCT00200551
Study type	Interventional
Source	Nantes University Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	January 2001
Completion date	April 2010

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06026592` - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Active, not recruiting	`NCT02444429` - 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation	Phase 3
Completed	`NCT02238418` - Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.	Phase 4
Completed	`NCT01729494` - Belatacept Early Steroid Withdrawal Trial	Phase 4
Terminated	`NCT01436305` - Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation	Phase 2
Terminated	`NCT01276834` - Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation	Phase 4
Completed	`NCT02843295` - Catalytic Antibodies to Predict Uninvasively Late Transplant Failure	N/A
Completed	`NCT00842699` - Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab	N/A
Completed	`NCT00525681` - Interaction Between Rimonabant and Cyclosporine and Tacrolimus	Phase 4
Completed	`NCT00189735` - A Study to Evaluate FK778 in Kidney Transplant Patients	Phase 2
Completed	`NCT00776750` - Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients	Phase 4
Recruiting	`NCT04052867` - Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy	N/A
Recruiting	`NCT03114826` - Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients	N/A
Completed	`NCT02587052` - A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
Completed	`NCT02020642` - Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx)	N/A
Completed	`NCT01435291` - AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation	Phase 4
Recruiting	`NCT01001065` - Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis	N/A
Completed	`NCT00978965` - Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs
Recruiting	`NCT00903188` - Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation	Phase 4
Completed	`NCT00419575` - Renal Transplantation With Immune Monitoring	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.